This week on SG Talks, we welcome Fanny Giannou, Co-Founder of Alithea Bio, a pioneering startup transforming cancer treatment through innovative immunotherapy solutions. Fanny shares her journey and the vision behind Alithea Bio, illustrating how the company blends cutting-edge science and technology to create safer, more effective cancer therapies.
In this episode, she delves into how Alithea empowers biotech innovators with advanced tools for target discovery, validation, and toxicity prediction, driving progress in the fight against cancer. Tune in to discover how Alithea Bio is shaping the future of healthcare and making a profound impact on this global challenge. Don’t miss this inspiring conversation!
Fanny Giannou is a Women TechEU 2024 awardee and an HSG/ETH Executive MBAX candidate. She holds a Master’s in International Economics from Sorbonne University and Humboldt Universität.With over 15 years of experience in international business development, Fanny has worked in strategic and management roles for multinational companies before founding Alithea Bio. Since 2022, she has led Alithea’s international business strategy, securing funding for the CyberChampion 2024 company and significantly increasing revenues.Leveraging Alithea’s global reputation in the TCR field, she is now reinventing its data and AI strategy to position the company as a leader in precision immunotherapy.